If the research is terminated prematurely or temporarily, it is the responsibility of the chief investigator (on behalf of the sponsor) to notify the Medicines and Healthcare products Regulatory Agency (MHRA) (if applicable) and Research Ethics Committees (REC) within 15 days explaining the reasons for this. Termination of clinical trials should be reported using the end of trial form.
Please inform the Research Governance, Ethics & Assurance Team promptly of any such suspension or early end. This applies to any research terminated early, for any reason, even if no participants have been recruited.
